Generic Name: N/A

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Monoclonal Antibodies

Company: CytoDyn

Approval Status: Experimental

Generic Version Available: No

Experimental Code: PRO 140

Drug Recommendation

PRO 140 is not yet approved by the U.S. Food and Drug Administration, nor has it been been reviewed for inclusion in the DHHS list of recommended HIV treatments.

General Info

PRO 140 is an experimental HIV medication. It is an entry inhibitor. PRO 140 contains genetically engineered antibodies, known as monoclonal antibodies. These antibodies bind to the CCR5 coreceptor on CD4 cells. Once they do this, HIV cannot successfully bind with the surface of these cells, thus preventing the virus from infecting them.

A Phase III trial of PRO 140 began in October 2015 as an adjunct to standard antiretroviral therapy. A Phase IIb study of PRO 140 monotherapy for the maintenance of viral suppression in subjects who are stable on combination antiretroviral therapy is expected to be completed in October 2016.


Adult Dose: A dose for PRO 140 has not yet been determined. The drug is administered via subcutaneous injection once a week.

Pediatric Dose: N/A

Dosing Info: N/A

Side Effects

Information regarding the safety and possible side effects of PRO 140 in HIV-positive people has not yet ben reported. Studies to determine the potential side effects of PRO 140 are planned or ongoing.

Drug Interactions

No studies have yet reported whether PRO 140 may interact with other drugs. Trials to determine potential drug interactions are planned or ongoing. PRO 140 might interact with other medications, including those used to treat HIV. It is important that your personal physician and/or the research nurse or study investigator be aware of all drugs you are taking, including those you buy without a prescription.

Last Reviewed: February 4, 2017